Highlights
IIA supported (ever)1 patentProfile claimed by owner
About
Tissue Engineering for Insulin Therapy Alternative
Betalin Therapeutics seeks to eliminate the need for insulin injections and glucose testing in diabetes patients with its proprietary transplanted Engineered Micro Pancreas (EMP). The EMP technology helps create connective tissue that enables the body's beta cells to function properly and produce adequate and functional insulin.
Betalin Therapeutics licensed the novel EMP technology developed at the Hebrew University of Jerusalem, Israel, in an exclusive worldwide agreement in 2015. The Hebrew University continues to partner with Betalin Therapeutics to support the research and development.
Identity
| Name | Betalin Therapeutics |
|---|---|
| Slug | betalin-therapeutics |
| Type / kind | startup |
| Crunchbase ID | betalin-therapeutics |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgIOf0o4KDA |
Status
| Status | active |
|---|---|
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District,Jerusalem District |
| HQ city | Jerusalem |
| HQ address | Jerusalem Bio Park (JBP) Minrav Bldg |
Web & social
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyBiomaterials & Tissue Engineering
Technologies
Materials & SubstancesImplantsBiologicalsCells
Target customers
Healthcare & Life SciencesHealthcareProvidersPatients
Business models
B2B2C
Tags
bioconvergencediabetescell-therapybiological-therapyregenerative-medicinebiopharmaceuticalbiotechnologychronic-patientstreatments
Funding
| Total raised | $11.1M |
|---|---|
| Current stage | Series A |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}